Alkermes starts Phase III trial of ALKS 8700 to treat multiple sclerosis

Ireland-based biopharmaceutical firm Alkermes has started a Phase III clinical trial of ALKS 8700 for the treatment of relapsing forms of multiple sclerosis (MS). (Source: Drug Development Technology)